Highlights
- Second quarter total revenues rose 11% to $628.7 million, including $570.6 million of CABOMETYX net product revenues, up 10%.
- GAAP net income increased to $212.1 million, or $0.82 per diluted share, from $184.8 million, or $0.65.
- The FDA assigned a December 3, 2026 target action date for zanzalintinib with atezolizumab in previously treated colorectal cancer.
- The company had repurchased $902.2 million of stock under two programs and held $1.4 billion in cash and marketable securities.
Exelixis, Inc. (NASDAQ:EXEL) shares were trading near their 52-week high at USD 64.47 on October 21, 2026, up 0.12%. The oncology company reported second quarter results in a Form 10-Q filed August 5, announced a new $750 million buyback in May, and has an FDA decision date of December 3 on its lead pipeline drug.
Based in Alameda, California, Exelixis is a Delaware corporation that describes itself as an oncology company developing next-generation medicines and regimens. It has produced four marketed products: CABOMETYX and COMETRIQ, both formulations of cabozantinib; COTELLIC, marketed with Genentech; and MINNEBRO, licensed to Daiichi Sankyo in Japan. Cabozantinib sales account for the majority of revenues, and Ipsen and Takeda hold rights outside the United States. Its lead clinical asset is zanzalintinib. The company uses a 52- or 53-week fiscal year ending on the Friday closest to December 31.
CABOMETYX Drives Higher Revenue and Profit
Total revenues for the second quarter of 2026 were $628.7 million, up from $568.3 million. Net product revenues were $573.0 million, up 10%, with CABOMETYX at $570.6 million. The company said a 6% rise in CABOMETYX units sold, reflecting demand in first-line advanced renal cell carcinoma with nivolumab and in neuroendocrine tumors, was the main factor, with price adding about 4%. Collaboration revenues rose 15% to $55.7 million, including Ipsen royalties of $50.5 million.
Income from operations was $248.4 million, versus $213.6 million. Research and development expenses rose to $212.0 million from $200.4 million, and selling, general and administrative expenses rose to $147.6 million from $134.9 million. The provision for income taxes was $50.6 million. Net income was $212.1 million, or $0.85 per basic share and $0.82 per diluted share, against $184.8 million, or $0.68 and $0.65. For six months, net income was $422.5 million, or $1.60 per diluted share, and operating cash flow was $559.6 million, versus $260.4 million.
Pipeline Progress, Setbacks and Legal Risks
The FDA accepted the zanzalintinib new drug application in February 2026 under standard review, with a target action date of December 3, 2026. The filing rests on STELLAR-303, which showed a 20% reduction in the risk of death versus regorafenib in the intention-to-treat population in an October 2025 analysis. In June 2026, however, the final analysis of the other primary endpoint, overall survival in patients without active liver metastases, showed a trend favoring the combination that was not statistically significant.
The company started the STELLAR-201 meningioma trial in April, announced new STELLAR-002 expansion cohorts in prostate and bladder cancer, and signed a Merck supply collaboration for the planned STELLAR-316 colorectal cancer trial. It also faces generic challenges to CABOMETYX. The filing lists abbreviated applications from MSN, Teva, Cipla, Biocon, Sun and Accord, plus 505(b)(2) applications from Azurity, Handa and Almatica, and a consolidated trial in Delaware is scheduled for November 2, 2026. The company warns that approval and launch of a follow-on product could significantly decrease U.S. CABOMETYX revenues.
Capital Returns and Outlook
In October 2025, the board authorized a repurchase of up to $750 million, which has been completed, and in May 2026 it approved up to $750 million more through December 31, 2027. By June 30, the company had bought 20.2 million shares for $902.2 million, leaving about $597.8 million. Cash, cash equivalents and marketable securities were $1.4 billion, down from $1.7 billion at December 31, 2025, largely reflecting repurchases. The company expects its resources to fund operations for at least twelve months and beyond.
The 10-Q provides no numerical financial guidance. It projects that net product revenues may increase over the rest of 2026 and that research and development expenses may rise. Top-line results from the STELLAR-304 kidney cancer trial are expected in the second half of 2026, depending on event rates, and STELLAR-202 is expected to start in that period. These are company expectations from a report filed August 5, 2026.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...